Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

NCT07179900 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: QL1706
RADIATION: Radiotherapy
DRUG: Sintilimab
DRUG: Bevacizumab

Sponsor

Hebei Medical University Fourth Hospital